The Medical Letter on Drugs and Therapeutics
FROM
ISSUE
1494
May 9, 2016
View Complete Issue         Table of Contents 2019 
Ixekizumab (Taltz) - A Second IL-17A Inhibitor for Psoriasis
Subscribers: Log in to read full article.  Not a subscriber?  Subscribe or purchase article.
Ixekizumab (Taltz) - A Second IL-17A Inhibitor for Psoriasis
May 9, 2016 (Issue: 1494)
The FDA has approved ixekizumab (Taltz – Lilly), an injectable humanized interleukin (IL)-17A antagonist, for treatment of adults with moderate to severe plaque psoriasis who are candidates for systemic therapy or phototherapy. Ixekizumab is...more
The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this article?  Gain access below.

Subscribe
Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Unlimited online access to current and past issues (1988 - present)
  • Mobile App for iOS, Android, and Kindle Fire
  • FREE online per issue CME/CE
Purchase this article:
Title: Ixekizumab (Taltz) - A Second IL-17A Inhibitor for Psoriasis
Article code: 1494b
 Electronic, downloadable article - $45


Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.